UPDATE: RBC Capital Starts Ovid Therapeutics Inc (OVID) at Outperform

September 4, 2019 5:45 AM EDT
Get Alerts OVID Hot Sheet
Price: $3.78 -1.05%

Rating Summary:
    5 Buy, 3 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 17 | Down: 13 | New: 41
Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

(Updated - September 4, 2019 6:19 AM EDT)

(updated to add analyst comments)

RBC Capital analyst Brian Abrahams initiates coverage on Ovid Therapeutics Inc (NASDAQ: OVID) with a Outperform rating and a price target of $12.00.

The analyst commented, "We believe the Street is overlooking signals of activity for lead drug OV101 that suggest its potential for success in Angelman's Syndrome - a high unmet need orphan disease we believe could provide $280M in out-year revs, with additional potential for the drug in Fragile X Syndrome (FXS) and for OV935 in refractory epilepsies. We believe the considerable upside opportunity upon success as these under-the-radar programs progress creates a compelling reward/risk."

For an analyst ratings summary and ratings history on Ovid Therapeutics Inc click here. For more ratings news on Ovid Therapeutics Inc click here.

Shares of Ovid Therapeutics Inc closed at $1.76 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

RBC Capital